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Over the last few decades, celiac disease has become 
one of the most extensively studied immune-mediated 
disorders worldwide. Erroneously considered as a rare 
condition in the past, its prevalence is now estimated to 
be about 1% in the majority of countries, including non-
Western ones [1]. Increasing awareness among physi-
cians of the wide spectrum of clinical manifestations and 
laboratory abnormalities in otherwise healthy subjects 
has accounted for this phenomenon. Notwithstanding, 
beyond underdiagnosis, reports based on serological 
studies in different countries have suggested that the true 
incidence of this entity is growing when compared to the 
1940s or 1970s [2–4]. Taking all this into account, it is 
reasonable to state that celiac disease will have a greater 
impact on our clinical practice in the near future.
In this issue of GE – Portuguese Journal of Gastroenter-
ology, Silva et al. [5] report on the predictive factors and 
clinical impact of achieving histological recovery in celiac 
patients in clinical and serological remission. The authors 
verified that only about a third of the individuals had his-
tological normalization upon endoscopic reassessment, 
which was performed within 12 and 24 months of gluten-
free diet (GFD) initiation. Being a retrospective, observa-
tional study, their report could not be exempt of limita-
tions, one of which is the selection bias due to the fact that 
endoscopic evaluation was not compulsory. Nonetheless, 
since patients’ refusal to perform endoscopy is not un-
common in our clinical practice, this study presents an 
interesting analysis of the outcomes in regard to this par-
ticularly controversial topic in a real-life setting.
In contrast to its role for evaluation of nonresponsive 
celiac disease, the need for follow-up intestinal biopsies 
to confirm mucosal healing in asymptomatic patients 
with negative serology after GFD remains a matter of dis-
cussion between experts. Several reports suggested that 
persistent long-term villous atrophy could be associated 
with higher risk of forthcoming relapse, severe complica-
tions, including bone disease and lymphoma, and a trend 
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to higher mortality [6–8]. However, some of those results 
have met criticism for their inadequate power, potential 
for referral bias, and lack of causality [9]; moreover, since 
they did not study the specific situation of patients who 
adhered and clinically responded to GFD, it is not possi-
ble to extrapolate the outcomes for those subjects. On the 
contrary, it is consensual that histological recovery is slow 
or may even not occur in a substantial proportion of 
adults during follow-up as long as 5 years; the reasons be-
hind this occurrence are still unknown [8–11].
The most widespread explanation for the maintenance 
of histological damage despite strict and longstanding 
GFD is persistent but minimal gluten exposure. In those 
cases, gluten ingestion would not be significant enough to 
cause symptoms or to increase antibody titers but suffi-
cient to produce some degree of intestinal inflammation 
and atrophy. In fact, some authors affirm that a total gluten 
eviction is not possible, thus hypothesizing that patients 
may continue to be chronically exposed to small quantities 
of gluten throughout life [12, 13]. The correlation between 
the amount of gluten intake and the development of mu-
cosal lesions is not clearly established, probably depending 
on a multiplicity of factors such as age, genetics, profiles of 
immune response, and microbiome [14].
Another plausible justification for the absence of mu-
cosal healing could be related with long-lasting local im-
mune response despite complete gluten elimination. In-
terestingly, histological normalization with GFD tends to 
occur more often in children than in adults [11]. Concur-
rently, several authors have described the possible devel-
opment of gluten tolerance and disease latency following 
years of remission with GFD, namely in children or adults 
who were diagnosed during childhood [15–18]. In oppo-
sition to those, other patients might develop some degree 
of persistent mucosal immune response, regardless of 
gluten avoidance and consequent antibody normaliza-
tion, maintaining long-term histological damage. Taking 
these data into account, one can hypothesize that such 
tendency to resolution versus persistence of intestinal im-
mune response may be different among age groups.
Disregarding the underlying mechanisms associated 
with the failure to achieve histological normalization, the 
fundamental question is whether it translates to any rel-
evant prognostic effect or change in the management of 
such patients. In accordance with previous data, Silva et 
al. [5] did not find any clinical impact in their cohort. 
They noticed that, in individuals with lower histological 
grades at diagnosis, complete histological improvement 
could be easier – or at least faster – to obtain; however, 
that could be in contrast to their findings regarding 
the relationship with lower levels of transferrin satura- 
tion at baseline, which, according to their suggestion, 
could mean that individuals with more severe – or pro-
longed – disease would recover more promptly. 
Another important question to raise is whether com-
plete histological normalization should be the target to 
pursue. Although some studies demonstrated that in-
traepithelial lymphocytosis appears to improve earlier 
than other lesions and to be a valuable marker for ongoing 
gluten intake, it is undeniable that their existence can also 
be linked to a variety of other conditions [8, 19]. Further-
more, evidence showed that, if there is any prognostic im-
pact attributable to persistent histological abnormalities, 
the presence of villous atrophy rather than intraepithelial 
lymphocytosis would be the determinant factor [6, 7]. Sil-
va et al. [5] only identified histological remission, defined 
as Marsh 0, in about one third of their patients; however, 
they found histological improvement, which is considered 
a reasonable goal for some experts, in about 80% of the 
cases, a result that is similar to previous publications.
In conclusion, this study reinforces that, in spite of all 
advances in the comprehension of the pathophysiology of 
celiac disease and its management, several doubts remain 
in relation to what is the most appropriate strategy for 
follow-up and surveillance. Future studies are required to 
specify the proper definition of histological remission, to 
establish the ideal timing for its evaluation and, above all, 
to determine if its accomplishment should be the ideal 
target or rather an unnecessary and unrealistic goal.
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